OTC · RTGN
RetinalGenix Technologies Inc.
$3.99$0.00 (0.0%)
RetinalGenix Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.52% below the high.
Loading market information…
OTC · BIOGF · USD
Stock price, earnings
Quote as of Aug 30, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biocartis Group N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biocartis Group N.V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions. These offerings aim to benefit patients, clinicians, healthcare payers, and the wider healthcare industry, with a particular emphasis on the field of oncology. Central to their product portfolio is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This cutting-edge technology delivers vital molecular information, which is instrumental in both selecting appropriate treatments and continuously monitoring their effectiveness. The company provides a diverse array of Idylla tests, including mutation analyses for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Beyond cancer diagnostics, they also offer panels for infectious diseases, specifically Idylla SARS-CoV-2/Flu/RSV and standalone SARS-CoV-2 tests. Additionally, their SeptiCyte RAPID test offers quick assessment of host response. For research purposes, Biocartis supplies various assays for detecting mutations, including those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis actively engages in strategic collaborations. They have partnered with Amgen to evaluate the Idylla RAS testing capabilities, aiming for rapid, decentralized diagnostics and faster access to crucial RAS biomarker data via the Idylla platform. Another collaboration with Bristol-Myers Squibb Company focuses on the regulatory approval and application of the Idylla MSI test in conjunction with immuno-oncology therapies. Furthermore, Biocartis holds a licensing, development, and commercialization agreement with GeneproDx for integrating the novel ThyroidPrint genomic test onto the Idylla platform. Founded in 2007, Biocartis Group N.V. operates from its headquarters located in Mechelen, Belgium.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:42 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.99$0.00 (0.0%)
RetinalGenix Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.52% below the high.
$1.00$0.00 (0.0%)
Taihe Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.7% below the high.
$0.26$0.00 (0.0%)
Karolinska Development AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
SEK 1.67-SEK 0.04 (-2.22%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.75% below the high.
$0.07$0.00 (0.0%)
Elegance Optical International Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.45$0.00 (0.0%)
Goodness Growth Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.55-$0.01 (-1.1%)
MCI Onehealth Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.47% below the high.
€1.18-€0.02 (-1.67%)
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
